Data from A Targeted RNAi Screen of the Breast Cancer Genome Identifies <i>KIF14</i> and <i>TLN1</i> as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer

Abstract

<div>Abstract<p><b>Purpose:</b> To identify biomarkers within the breast cancer genome that may predict chemosensitivity in breast cancer.</p><p><b>Experimental Design:</b> We conducted an RNA interference (RNAi) screen within the breast cancer genome for genes whose loss-of-function enhanced docetaxel chemosensitivity in an estrogen receptor–negative, progesterone receptor–negative, and Her2-negative (ER−, PR−, and Her2−, respectively) breast cancer cell line, MDA-MB-231. Top candidates were tested for their ability to modulate chemosensitivity in 8 breast cancer cell lines and to show <i>in vivo</i> chemosensitivity in a mouse xenograft model.</p><p><b>Results:</b> From ranking chemosensitivity of 328 short hairpin RNA (shRNA) MDA-MB-231 cell lines (targeting 133 genes with known somatic mutations in breast cancer), we focused on the top two genes, <i>kinesin family member 14</i> (<i>KIF14</i>) and <i>talin 1</i> (<i>TLN1</i>). KIF14 and TLN1 loss-of-function significantly enhanced chemosensitivity in four triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, HCC38, HCC1937, and Hs478T) but not in three hormone receptor–positive cell lines (MCF7, T47D, and HCC1428) or normal human mammary epithelial cells (HMEC). Decreased expression of KIF14, but not TLN1, also enhanced docetaxel sensitivity in a Her2-amplified breast cancer cell line, SUM190PT. Higher <i>KIF14</i> and <i>TLN1</i> expressions are found in TNBCs compared with the other clinical subtypes. Mammary fat pad xenografts of KIF14- and TLN1-deficient MDA-MB-231 cells revealed reduced tumor mass compared with control MDA-MB-231 cells after chemotherapy. <i>KIF14</i> expression is also prognostic of relapse-free and overall survival in representative breast cancer expression arrays.</p><p><b>Conclusion:</b> KIF14 and TLN1 are modulators of response to docetaxel and potential therapeutic targets in TNBC. <i>Clin Cancer Res; 19(8); 2061–70. ©2013 AACR</i>.</p></div>